Danaher Co. (NYSE:DHR) Shares Sold by Folger Nolan Fleming Douglas Capital Management Inc.

Folger Nolan Fleming Douglas Capital Management Inc. cut its holdings in shares of Danaher Co. (NYSE:DHR) by 3.2% in the 4th quarter, Holdings Channel reports. The firm owned 3,911 shares of the conglomerate’s stock after selling 130 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Danaher were worth $905,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BKM Wealth Management LLC purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $29,000. OFI Invest Asset Management purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $30,000. Rakuten Securities Inc. purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $36,000. Finally, GHP Investment Advisors Inc. lifted its position in shares of Danaher by 540.0% in the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after acquiring an additional 135 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR traded up $0.78 during midday trading on Friday, reaching $246.58. The stock had a trading volume of 2,710,446 shares, compared to its average volume of 2,710,897. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The firm’s fifty day simple moving average is $248.87 and its 200-day simple moving average is $231.08. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37. The stock has a market capitalization of $182.64 billion, a P/E ratio of 41.77, a PEG ratio of 3.78 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business posted $2.36 EPS. On average, equities research analysts forecast that Danaher Co. will post 7.65 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insiders Place Their Bets

In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now directly owns 14,129 shares in the company, valued at approximately $3,548,498.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold 106,565 shares of company stock worth $26,641,364 in the last ninety days. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of several research analyst reports. Raymond James upped their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Citigroup increased their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays increased their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Royal Bank of Canada increased their target price on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Bank of America increased their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $270.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.